Modeling and Simulation - PK/PD Archives | Page 13 of 39 | Certara

White Paper

Drug Asset Evaluation: Increasing “Probability of Success” of a Deal

Certara’s due diligence/asset evaluation teams are comprised of drug development and commercialization experts who advise…

CertaraAugust 24, 2017

Publication

Parent‐metabolite Pharmacokinetic Modeling and Pharmacodynamics of Veliparib (ABT‐888), a PARP Inhibitor, in Patients with BRCA 1/2–mutated Cancer or PARP‐sensitive Tumor Types

CertaraAugust 1, 2017

Publication

Response Analysis of Alvocidib (Flavopiridol) Treatment by Bolus or Hybrid Administration in Newly Diagnosed or Relapsed/Refractory Acute Leukemia Patients

CertaraJuly 15, 2017

Publication

Interdisciplinary Pharmacometrics Linking Oseltamivir Pharmacology, Influenza Epidemiology and Health Economics to Inform Antiviral Use in Pandemics

CertaraJuly 1, 2017

Publication

Time Dependent Pharmacokinetics of Pembrolizumab in Patients with Solid Tumor and Its Correlation with Best Overall Response

CertaraJune 1, 2017

On-Demand Webinar

Obeticholic Acid—From PK Model to Drug Label

Watch this webinar with Jeffrey Edwards to learn how he used physiologic pharmacokinetic modeling to…

CertaraJune 1, 2017

Blog

Using Pharmacokinetics to Assure Chemical Food Safety

As a veterinarian, I’m responsible for the health and welfare of my animal patients. Sometimes,…

CertaraMay 12, 2017

Publication

Evaluation of Dosing Strategy for Pembrolizumab for Oncology Indications

CertaraMay 1, 2017

Publication

Effect of Disease-related Changes in Plasma Albumin on the Pharmacokinetics of Naproxen in Male and Female Arthritic Rats

CertaraMay 1, 2017

Publication

Isoniazid Clearance is Impaired Among Human Immunodeficiency Virus/Tuberculosis Patients with High Levels of Immune Activation

CertaraApril 1, 2017

© 2025 Certara. All Rights Reserved. | Privacy policy